Osimertinib, an irreversible third‐generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI), improves survival in patients with EGFR‐mutated non‐small‐cell lung cancer (NSCLC). Here, EGFR is linked to non-small cell lung carcinoma.